TY - JOUR
T1 - ANRIL's Epigenetic Regulation and Its Implications for Cardiovascular Disorders
AU - Moglad, Ehssan
AU - Kaur, Parjinder
AU - Menon, Soumya V.
AU - Abida,
AU - Ali, Haider
AU - Kaur, Mandeep
AU - Deorari, Mahamedha
AU - Pant, Kumud
AU - Almalki, Waleed Hassan
AU - Kazmi, Imran
AU - Alzarea, Sami I.
N1 - Publisher Copyright:
© 2024 Wiley Periodicals LLC.
PY - 2024/12
Y1 - 2024/12
N2 - Cardiovascular disorders (CVDs) are a major global health concern, but their underlying molecular mechanisms are not fully understood. Recent research highlights the role of long noncoding RNAs (lncRNAs), particularly ANRIL, in cardiovascular development and disease. ANRIL, located in the human genome's 9p21 region, significantly regulates cardiovascular pathogenesis. It controls nearby tumor suppressor genes CDKN2A/B through epigenetic pathways, influencing cell growth and senescence. ANRIL interacts with epigenetic modifiers, leading to altered histone modifications and gene expression changes. It also acts as a transcriptional regulator, impacting key genes in CVD development. ANRIL's involvement in cardiovascular epigenetic regulation suggests potential therapeutic strategies. Manipulating ANRIL and its associated epigenetic modifiers could offer new approaches to managing CVDs and preventing their progression. Dysregulation of ANRIL has been linked to various cardiovascular conditions, including coronary artery disease, atherosclerosis, ischemic stroke, and myocardial infarction. This abstract provides insights from recent research, emphasizing ANRIL's significance in the epigenetic landscape of cardiovascular disorders. By shedding light on ANRIL's role in cellular processes and disease development, the abstract highlights its potential as a therapeutic target for addressing CVDs.
AB - Cardiovascular disorders (CVDs) are a major global health concern, but their underlying molecular mechanisms are not fully understood. Recent research highlights the role of long noncoding RNAs (lncRNAs), particularly ANRIL, in cardiovascular development and disease. ANRIL, located in the human genome's 9p21 region, significantly regulates cardiovascular pathogenesis. It controls nearby tumor suppressor genes CDKN2A/B through epigenetic pathways, influencing cell growth and senescence. ANRIL interacts with epigenetic modifiers, leading to altered histone modifications and gene expression changes. It also acts as a transcriptional regulator, impacting key genes in CVD development. ANRIL's involvement in cardiovascular epigenetic regulation suggests potential therapeutic strategies. Manipulating ANRIL and its associated epigenetic modifiers could offer new approaches to managing CVDs and preventing their progression. Dysregulation of ANRIL has been linked to various cardiovascular conditions, including coronary artery disease, atherosclerosis, ischemic stroke, and myocardial infarction. This abstract provides insights from recent research, emphasizing ANRIL's significance in the epigenetic landscape of cardiovascular disorders. By shedding light on ANRIL's role in cellular processes and disease development, the abstract highlights its potential as a therapeutic target for addressing CVDs.
KW - ANRIL
KW - atherosclerosis
KW - cardiovascular disorders
KW - coronary artery disease
KW - ischemic stroke
KW - lncRNAs
KW - myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85211119322&partnerID=8YFLogxK
U2 - 10.1002/jbt.70076
DO - 10.1002/jbt.70076
M3 - Review article
C2 - 39620406
AN - SCOPUS:85211119322
SN - 1095-6670
VL - 38
JO - Journal of Biochemical and Molecular Toxicology
JF - Journal of Biochemical and Molecular Toxicology
IS - 12
M1 - e70076
ER -
